Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Develops novel multifunctional antibodies for oncology and immunology & inflammation indications
Pitching abrdn? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room